The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $61.00, about 46.7% above its August 12 closing price of $41.58
The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 23 three months ago
Result drivers and key details
HEMANGEOL relaunch - Addition of HEMANGEOL sales and faster-than-expected patient conversion drove revenue growth
Pediatric endocrinology growth - Strong year-over-year growth in pediatric endocrinology portfolio, including new and existing products
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
$0.43
$0.11 (4 Analysts)
Q2 EPS
$0.35
Q2 Net Income
$11.58 mln
Q2 revenue jumps on HEMANGEOL relaunch
U.S. rare disease drugmaker's Q2 revenue rose 99% yr/yr, driven by HEMANGEOL relaunch
Adjusted EPS for Q2 beat analyst expectations
Company raised full-year 2026 revenue guidance to over $145 mln
ETON•
